Navigation Links
Three Industry Veterans Join Ascension Orthopedics
Date:6/13/2008

AUSTIN, Texas, June 13 /PRNewswire/ -- Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the hiring of three orthopedic executives, William F. Warrender, Jr., John F. Walters and David C. Furr, as new Senior Vice Presidents. Their extensive background and experience will make a substantial contribution to the future growth of Ascension.

Bill Warrender joined Ascension on April 14 as Senior Vice President of Global Sales. He brings more than 25 years of sales, marketing and general management experience to the executive team. Warrender was most recently based in Pennsylvania as President of Medartis, Inc. and has held management positions with Encore Orthopedics, Smith & Nephew, and Zimmer, among others. "Bill will contribute a valuable 'can-do' spirit to our sales team," states Andrew J. Miclot, President and CEO of Ascension. Warrender has a B.S. in Marketing and Management from LaSalle University and an M.B.A. in Management and Finance from the University of Notre Dame.

John Walters assumed the role of Senior Vice President of Global Marketing on June 2. He has been active in the orthopedic medical device field for over 20 years, having high-level positions at market-leading corporations including Depuy, Johnson & Johnson and Wright Medical Technologies. "John has a combination of marketing, development and financial experience in orthopedics that will be an important asset as we work to reposition ourselves and expand within the extremities market," says Miclot. Walters received his B.S. degree in Biology and his M.B.A. in Management and Finance from the University of Arizona.

David Furr also joined the executive team on June 2, as Senior Vice President of Quality Assurance, Regulatory Affairs and Clinical Affairs. Prior to accepting this new role at Ascension, Furr was president and principal of FDC Services, LLC, a consulting firm specializing in quality, regulatory and clinical issues for the orthopedic, medical device and pharmaceutical industries. "He brings the kind of seasoned leadership that will be required as we continue to branch out in a worldwide market where regulations constantly evolve," explains Miclot. During his nearly 30 years of experience, Furr has also held senior positions at Boston Scientific, Bristol-Myers Squibb/Zimmer and Greer Laboratories. He holds a B.S. degree in Chemistry from Texas State University and an M.S. degree in Quality Assurance and Regulatory Affairs from the Temple University School of Pharmacy.

Ascension Orthopedics secured $21 million in a Series D financing in January 2008. Frazier Healthcare Ventures lead this round of funding as the majority investor. "We appreciate Frazier's investment in Ascension. Their commitment to our company has enabled us to hire these talented executives," said Miclot.

About Ascension Orthopedics, Inc.

Ascension Orthopedics started in Austin, Texas in 1996. In 2001, Ascension received FDA PMA approval for its first product, an innovative pyrolytic carbon total joint replacement for the MCP (Knuckle) joint of the hand. The company has since increased its joint replacement product line to include implants for the shoulder, elbow, wrist, fingers and toes. Ascension Orthopedics is dedicated to the development of orthopedic implants for upper and lower extremities. Ascension's mission is to help surgeons treat patients suffering from pain and dysfunction, by developing state of the art orthopedic products. Ascension Orthopedics sells products in the United States and in more than 20 foreign countries worldwide. For further information, please visit http://www.ascensionortho.com/.

About Frazier Healthcare

Investing since 1991, Frazier Healthcare Ventures is one of the nation's leading providers of venture and growth equity capital to emerging biopharma, medical device and healthcare service companies. With more then $1.8 billion under management, Frazier Healthcare has invested in over 100 healthcare companies that cover the entire developmental spectrum from seed stage to PIPEs to acquisitions of cash generating companies. Frazier Healthcare is nationally known for its highly experienced 23 member investment team, which collectively brings to bear a tremendous breadth of healthcare industry and investment experience. The team's expertise encompasses product development and launch, clinical trial implementation and design, academic research, clinical practice, industry operating experience, and business development. For more information, please visit http://www.frazierhealthcare.com/.

FOR FURTHER INFORMATION CONTACT:

Andrew J. Miclot

President / CEO

Ascension Orthopedics, Inc.

512-836-5001


'/>"/>
SOURCE Ascension Orthopedics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
2. IntraHealths Family Planning Work in Rwanda Contributes to Near Three-Fold Increase in Contraceptive Use in Only Three Years
3. Three Miami Area Brothers and Physicians Assistant Charged In $110 Million Health Care Fraud Scheme
4. Three-peat: Nurture(R) Strikes Gold Again at NeoCon
5. Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar.
6. Prime Healthcare Services to Acquire Three Hospitals from Tenet Healthcare Corporation
7. U.S. News Ranks Cincinnati Childrens Among Top Three U.S. Childrens Hospitals
8. Three Miami Area Doctors and Six Others Charged in $56 Million Health Care Fraud Schemes
9. Alsius Corporation Awarded Three-Year Agreement With Premier, Inc.
10. The Doctors Channel Launches New Videos from Three Top Hospitals
11. Alsius Corporation Awarded Three-Year Agreement with HealthTrust Purchasing Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence now ... the most minimally invasive approaches. , Women who have had multiple vaginal births ... factors include surgery to the pelvic floor, connective tissue disorders, and obesity. Women ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood , ... medical and surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, ... non-surgical alternative for reduction of fat below the chin (aka the “double chin”). ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/5/2016)... ... , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon ... 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped ... Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- HemaFlo Therapeutics, Inc. announced today that the United States Patent ... covering the use of NephroFlow to treat acute kidney injury ... said, "We are pleased to secure our rights to such ... PhD, HemaFlo,s founder, said, "We are pleased to secure our ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ...
(Date:2/8/2016)... , Feb. 8, 2016  Dynatronics Corporation ... of advanced-technology medical devices and rehabilitation equipment for ... congratulates the Denver Broncos, football team for winning ... Cullimore Jr. , Chairman and Chief Executive Officer.  ... and we look forward to enhancing their athletic ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
Breaking Medicine Technology: